Health and Medicine
Jun. 21, 2020—The Outcomes Related to COVID-19 Treated with Hydroxychloroquine among In-patients with Symptomatic Disease (ORCHID) trial stopped enrolling new patients based on the fourth scheduled interim analysis showing no evidence of benefit or harm.
Jun. 18, 2020—On May 27, the All of Us Research Program launched the beta version of its cloud-based research platform, the Researcher Workbench.
Vanderbilt researcher Houra Merrikh named a finalist of the 2020 Blavatnik National Awards for Young Scientists, inducted to New York Academy of Sciences
Jun. 17, 2020—Biochemist Houra Merrikh has been named one of the nation’s rising stars in science for her work to reverse antimicrobial resistance.
Vanderbilt University partners with ACADIA Pharmaceuticals to develop novel treatments for central nervous system disorders
Jun. 16, 2020—Vanderbilt University’s Warren Center for Neuroscience Drug Discovery has entered into an exclusive worldwide licensing and collaboration agreement with San Diego-based ACADIA Pharmaceuticals Inc. to develop treatments for disorders like Alzheimer’s and schizophrenia.
Leader in Vanderbilt drug discovery efforts, Craig Lindsley named interim editor-in-chief of ACS Pharmacology & Translational Science
Jun. 12, 2020—Craig Lindsley, William K. Warren, Jr. Chair in Medicine and university professor of biochemistry, chemistry and pharmacology, has been named interim editor-in-chief of the journal "ACS Pharmacology & Translational Science."
Jun. 12, 2020—Vanderbilt University Medical Center investigators have used high-throughput robotic technology to rapidly study and classify variations in a gene linked to heart rhythm disorders and cardiac conditions.
Jun. 11, 2020—Vanderbilt researchers have developed what appears to be a simple and promising treatment for breast cancer metastasis.
Jun. 10, 2020—Vanderbilt University Medical Center scientists have identified a C. diff protein system that senses and captures heme (part of hemoglobin) to build a protective shield that fends off threats from our immune system and antibiotics.
Jun. 9, 2020—After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.